



Ambassadors Corporate Welcome Reception

March 23, 2010
Genzyme
Cambridge, MA

Special Guest
**Greg Bialecki, Secretary, Executive Office of
Housing & Economic Development**

Massachusetts 
It's all here.®

Company Profiles

Biocell Center Group

Biocell Center Group is the only company in the world offering the private preservation of amniotic fluid stem cells from the amniocentesis procedure. In October 2009, Biocell Center opened its U.S. headquarters in Medford, Massachusetts. Biocell Center selected Massachusetts because of its high concentration of leading medical centers and research institutions, and has been successfully partnering with the leading hospitals in the area and throughout the US, as well as collaborating with scientists in the field of amniotic fluid stem cell clinical research.

www.biocellcenter.com

Kate Torchilin, PhD, MBA, CEO

Biocius

BIOCIUS Life Sciences, Inc. is a privately held company committed to collaborating with researchers to advance drug discovery research. Using RapidFire® technology, BIOCIUS helps to eliminate bottlenecks for lead discovery and in vitro ADME (absorption, distribution, metabolism and elimination) The RapidFire system enables researchers to gain a more complete understanding of the biochemical properties of potential lead compounds, including potential liabilities in drug-drug interactions using high-throughput mass spectrometry. In December of 2009, BIOCIUS spun out of BioTrove Inc. Biocius is located in Woburn MA.

www.biocius.com

Jeffrey C. Leathe, CEO

Edimer Pharmaceuticals

Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED). XLHED is a rare, orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. Edimer is led by a team of seasoned biotechnology industry veterans with deep experience in drug development complemented by a strong network of world-class clinical and scientific advisers. Based in Cambridge, Massachusetts, Edimer Pharma recently received venture funding from life science VC firm Third Rock Ventures.

www.edimerpharma.com

Neil Kirby, President and CEO

FloDesign Wind Turbine

Based in Wilbraham, Massachusetts, FloDesign Wind Turbine Corp. is developing high-efficiency shrouded wind turbines based on the application of mature aerospace technologies. FloDesign's turbine, which resembles a jet engine more than a traditional windmill, has demonstrated power output three to four times that of conventional turbines with similar rotor size. Recently, FloDesign raised \$34.5 million in Series B venture capital funding, and was awarded an \$8.3 million grant as part of the US Department of Energy's Advanced Research Projects Agency - Energy ("ARPA-E") program.

www.fdwat.com

Lars A. Andersen, CEO

Ginkgo BioWorks

Ginkgo BioWorks is a synthetic biology company focused on making biology easier to engineer. Ginkgo offers technology to speed the construction of DNA and enable reliable, rapid prototyping of engineered biological systems. Ginkgo BioWorks was founded in 2008 by five MIT PhDs.

Currently, Ginkgo is commercializing a suite of proprietary DNA assembly technologies optimized to simplify the rapid construction of metabolic pathways and other gene networks. Ginkgo's offices and lab space are located in the Marine Industrial Park in Boston, MA. A \$150 million loan from Life Tech Innovation Fund helped Ginkgo move to Boston where they can take advantage of the city's vast resources that will help them grow. Students, hospitals, healthcare institutions, and a thriving business community made Boston an easy choice.

www.ginkgobioworks.com

Jason Kelly, CEO

Icelandair

Icelandair, the flagship carrier of Iceland since 1937, offers non-stop service to Iceland from Boston, New York, Seattle, Minneapolis/St. Paul, Orlando, Halifax and Toronto. In August 2009, Icelandair moved its North American Headquarters from Columbia, MD to Quincy, MA. Many factors made Massachusetts the ideal location for Icelandair, including the close proximity to Boston Logan International, Icelandair's largest gateway. Icelandair has seen the benefit of having its entire North American Sales and Marketing team in Massachusetts and continuously works to boost commerce from New England while strengthening the bridge to Europe with its New England trade partners through Iceland.

www.icelandair.is

Thorsteinn Egilsson, General Manager – The Americas

The MENTOR Network

Founded in 1980, The MENTOR Network is a national network of local human services providers offering an array of quality, community-based services to adults and children with intellectual and developmental disabilities, acquired brain injury and other catastrophic injuries and illnesses and to youth with emotional, behavioral and medically complex challenges as well as their families. The MENTOR Network's corporate office is located in Boston. In September of 2009 The MENTOR Network signed a lease for office space at Osgood Landing in North Andover, Massachusetts for a new shared services center which will consolidate a number of back office functions in the areas of finance and human resources. The MENTOR Network could have chosen any of their national locations for this service center, but they decided to consolidate in Massachusetts. When fully staffed, it is expected that the new offices will bring 100 existing and new jobs to the town. The Osgood Landing site suits MENTOR's current needs and allows them the flexibility to expand if needed.

www.thementornetwork.com

Edward Murphy, CEO

NeoStem

NeoStem provides adult stem cell collection and storage services in addition to conducting extensive stem cell research. NeoStem expanded its laboratory infrastructure highlighted by a move to a new state of the art laboratory in Cambridge, MA in 2010. The 8,000SF laboratory is located between Harvard and MIT. Researchers will explore and evaluate various adult stem cells

and look to further understand the biology and potential of human stem cells. Five full time researchers have been hired and the laboratory will look to expand upon basic research and development by hiring additional researchers in 2010.

www.neostem.com

Robin L. Smith, CEO and Chairman of the Board

Nexage

Nexage is a leading developer of Mobile Advertising solutions that enable companies to maximize profitability from their mobile properties. Founded in 2006, its leading product is AdMax, a hosted Ad Optimization Platform that enables premium mobile publishers to fully control and maximize the profitability of their mobile services. The platform enables mobile publishers to maximize revenues from mobile ads while reducing internal operating expenses by more efficiently connecting to multiple ad networks. In 2009 Nexage moved its headquarters from Fremont, California to Waltham so the company could take advantage of Boston's rich talent pool and success in mobile advertising.

www.neostem.com

Devkumar Gandhi, Founder & CEO

Suntron

Suntron Corporation delivers complete vertically integrated electronics manufacturing services and solutions to support the entire life cycle of complex products within the Aerospace, Defense, Industrial, Medical, Network & Telecommunications, and Semiconductor Capital Equipment market segments. Suntron's capabilities include complete system integration level assembly as well as printed circuit boards, cables and harnesses. In addition, Suntron offers a complete suite of design and engineering services, quick turn prototyping and direct order fulfillment. Suntron's corporate headquarters are located in Phoenix Arizona, and the company will be consolidating its northeast operations to a new larger site in Methuen, MA, convenient for both its NH and Massachusetts employees.

www.suntroncorp.com

Ed Wheeler, President and CEO

Synageva BioPharma Corp.

Synageva BioPharma Corp. is a Massachusetts based biopharmaceutical company dedicated to discovering, developing and commercializing therapies for patients with rare conditions. The company has assembled a team with a proven track record of bringing treatments to market for rare and ultra rare diseases. Additionally, Synageva BioPharma has the ability to apply its proprietary protein expression technology, which is uniquely suited to develop novel orphan treatments for patients with unmet medical need. Synageva BioPharma Corp. opened its Massachusetts corporate headquarters in June 2008, completed a \$45 million financing round in October 2009 and is planning to expand its Massachusetts operations later this year.

www.synageva.com

Sanj K. Patel, President & CEO